Notably, patients receiving interferon-alpha, the JAK1/2 inhibitor (ruxolitinib), or combinations of these medications had higher rates of infection (61.4%, 68.2%, and 69.8%, respectively) compared to patients on hydroxyurea or no medications (36.9% and 55.6%, respectively). The gene discussed is JAK1; the disease is infection.